Press Releases | SeraCare

06/09/2021

LGC SeraCare Releases Clinical Diagnostic Quality Solution for SARS-CoV-2 Variant Analysis

LGC SeraCare has expanded its line of SARS-CoV-2 molecular quality solutions to include AccuPlex™ SARS-CoV-2 Variant Panel 1. The kit contains full SARS-CoV-2 genomic RNA with a focus on S-gene mutations in three prominent variants of concern (UK variant B.1.1.7, South Africa variant B.1.351, and Brazil variant P.1) with vials for each variant as well as wild type control and human RNase P negative control vials. This solution is compatible with multiple applications, including performance confirmation for existing SARS-CoV-2 molecular assays as well as SARS-CoV-2 variant genotyping or NGS assays.

04/01/2021

LGC SeraCare Launches SARS-CoV-2 Quality Solution for Antigen Testing

LGC SeraCare has released ACCURUN® SARS-CoV-2 Antigen Reference Material Kit, a new quality measurement tool to support SARS-CoV-2 antigen testing. It is formulated for use with test methods that detect the nucleocapsid (NP) protein of SARS-CoV-2 virus – the target for the majority of the SARS-CoV-2 antigen assays currently on the market.

01/26/2021

LGC SeraCare Launches SARS-CoV-2 Molecular Solution for Oral Fluid Testing

LGC SeraCare has expanded its innovative portfolio of SARS-CoV-2 quality solutions with the release of AccuPlex™ SARS-CoV-2 in Synthetic Oral Fluid reference material. The product is designed to support development and testing efforts around novel saliva-based SARS-CoV-2 diagnostics. It serves as an ideal research tool for assay developers as well as a complete quality solution for clinical laboratories employing such tests.

12/08/2020

LGC SeraCare Anti-SARS-CoV-2 Controls Kit now CE Marked

LGC SeraCare is pleased to announce that the ACCURUN® Anti-SARS-CoV-2 Reference Material Kit is now CE marked for in vitro diagnostic use (CE-IVD). With this change in regulatory status, the new product name is ACCURUN Anti-SARS-CoV-2 Controls Kit. Bearing the CE mark and IVD symbol signifies that the ACCURUN Anti-SARS-CoV-2 Controls Kit meets extensive design control requirements.

09/29/2020

LGC SeraCare Releases SARS-CoV-2 & Influenza Multiplexed Molecular Quality Solutions

LGC SeraCare has expanded the line of SARS-CoV-2 quality solutions to include products designed for use with multiplexed molecular assays that can detect SARS-CoV-2, influenza A/B and respiratory syncytial virus (RSV).

07/28/2020

LGC SeraCare SARS-CoV-2 Molecular Controls Kit now CE Marked

LGC SeraCare is pleased to announce that the AccuPlex™ SARS-CoV-2 Reference Material Kit v2 is now CE marked for in vitro diagnostic use (CE-IVD). With this change in regulatory status, the new product name is AccuPlex SARS-CoV-2 Molecular Controls Kit. Bearing the CE mark and IVD symbol signifies that the AccuPlex SARS-CoV-2 Molecular Controls Kit meets extensive design control requirements.

07/14/2020

LGC SeraCare Expands SARS-CoV-2 Molecular Solutions to Full Genome Coverage

LGC SeraCare continues to innovate its portfolio of products supporting SARS-CoV-2 diagnostics. Initially designed to target the published CDC and WHO consensus sequences, the new AccuPlex™ SARS-CoV-2 Verification Panel and Reference Material Kit are now available with full SARS-CoV-2 viral genome coverage. This expansion allows for compatibility with any SARS-CoV-2 assay target, while maintaining the safety features and performance monitoring advantages of AccuPlex technology.

07/09/2020

The Native Antigen Company Joins LGC

LGC, the UK based global leader in the life sciences sector has acquired the business of Oxford-based The Native Antigen Company (“NAC”), one of the world’s leading suppliers of high-quality infectious disease antigens and antibodies.

06/18/2020

LGC SeraCare Expands its SARS-CoV-2 Serology Offering with 11-Member, Positive-Patient Performance Panel

LGC SeraCare has released the AccuSet™ SARS-CoV-2 Performance Panel, intended for use by clinical laboratories and diagnostic manufacturers alike, to evaluate SARS-CoV-2 antibody assays.

05/28/2020

LGC SeraCare Expands its SARS-CoV-2 Offering to Include Serology Quality Solutions

LGC SeraCare has released ACCURUN® Anti-SARS-CoV-2 Reference Materials to address the critical need for clinical laboratories to be able to report antibody testing results with confidence, in response to the ongoing COVID-19 pandemic. The ACCURUN kit is designed to support assay installation as well as to monitor day-to-day assay performance, as required by CLIA, CAP, ISO-15189 and many other regulatory or accrediting bodies, providing a complete quality solution for SARS-CoV-2 antibody testing.

05/05/2020

LGC SeraCare's SARS-CoV-2 Quality Solutions to now include the S gene

In response to the critical need for accurate testing to combat the COVID-19 pandemic, LGC SeraCare continues to innovate and expand their novel AccuPlex™ SARS-CoV-2 Quality Solutions in support of improved diagnostic assay development and testing.

03/03/2020

LGC’s Clinical Diagnostics Business Unit expands production of AccuPlex™ COVID-19 reference materials to support global diagnostic assay development efforts

With the rapid global spread of the SARS-CoV-2 virus and the urgent need for reliable diagnostic solutions, LGC’s SeraCare Life Sciences is expanding production of their novel COVID-19 reference materials to include high titer stocks that serve as a valuable tool for diagnostic manufacturers.

03/27/2019

IQN Path Selects SeraCare Life Sciences for First-Ever Tumor Mutational Burden External Quality Assessment Program

SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers and clinical laboratories, announced today their successful selection as a technology partner in support of the first ever tumor mutational burden (TMB) external quality assessment (EQA) program being developed by the International Quality Network for Pathology (IQN Path).

11/26/2018

LGC Acquires Seracare Life Sciences Strengthening Its Position in Clinical Quality Control Tools

Today, LGC announced the acquisition of SeraCare Life Sciences, Inc., a manufacturer and leading partner to global in vitro diagnostics manufacturers and clinical laboratories.

10/29/2018

SeraCare Announces Exclusive Partnership with AccuRef Diagnostics

SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers and clinical laboratories, announced today an exclusive partnership with AccuRef Diagnostics, a Division of Applied StemCell, Inc., to market and sell their broad portfolio of CRISPR-engineered cell line reference materials.

10/22/2018

SeraCare Announces Launch of Expanded NTRK Reference Material Panel

SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers and clinical laboratories, announced today the commercial launch of an expanded neurotrophic tropomyosin receptor kinase (NTRK) RNA fusion reference material panel developed in a partnership with Bayer.

09/12/2018

Pioneering Survey of Clinical NGS QC Practices Proves Need for Purpose-Built QC Solutions to Standardize Industry

SeraCare Life Sciences has partnered with GenomeWeb to conduct a first-of-its-kind survey for clinical NGS labs with over 150 respondents providing comprehensive data detailing their QC management programs.

07/25/2018

SeraCare Announces the Expansion of Their Proprietary AccuPlex™ Technology Product Portfolio with the Launch of the AccuSpan™ HCV RNA Linearity Panel

Announcing the launch of their all-new AccuSpan™ HCV RNA Linearity Panel – the latest product built with their proprietary AccuPlex™ recombinant technology

04/17/2018

SeraCare Partners with NAVICAN on Implementation of Best-In-Class QC Workflow for TheraMap Precision Cancer Care™ Services

Leading NGS QC Software is integrated into their Philips IntelliSpace Genomics Platform

04/16/2018

SeraCare Announces Expansion of Industry’s Most Complete and Patient-Like ctDNA Reference Materials

Comprehensive circulating tumor DNA reference materials for NGS assay development, validation, and daily run controls